ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced the commencement of a global pivotal study for its lead asset, varlitinib, in biliary tract cancer, following the approval of ASLAN’s Investigational New Drug application by the United States Food and Drug […]
This post first appeared on Biotechin.asia – Your Daily Biotech And Healthca, please read the originial post: here
